Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very favourable analyst view
Very low or no dividends
Weak growth
Risk / Profitability
Risk: High
Profitability: Average
Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very favourable analyst view
Very low or no dividends
Weak growth
€ 0.14
About
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based...
About
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy...
